Remove Biopharma Remove Competition Remove Pharma
article thumbnail

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. The ‘Sectoral Systems of Innovation and the UK’s Competitiveness’ reports assess the value-added per capita of each sector and how they compare internationally.

article thumbnail

New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds

MedCity News

The post New Eli Lilly Eczema Drug Brings Competition and Dosing Edge Versus Sanofi, LEO Pharma Meds appeared first on MedCity News. Eli Lilly drug Ebglyss is now FDA-approved for atopic dermatitis, an inflammatory skin disorder also known as eczema. The biologic drug came from Lilly’s $1.1 billion acquisition of Dermira in 2020.

article thumbnail

FDA Nod for BridgeBio Brings New Competition to Blockbuster Pfizer Cardio Drug

MedCity News

BridgeBio Pharma claims its drug, Attruby, has an edge over a Pfizer drug as a treatment for cardiomyopathy caused by transthyretin-mediated amyloidosis. But new competition to both products could come soon from Alnylam Pharmaceuticals, now set to receive an FDA decision in this indication by late March.

article thumbnail

JPM24: Amgen CEO hopes to take a bite of competitive obesity market with unique approach

Fierce Pharma

After last year saw the rise of popular obesity treatments, biopharma's interest in the field only appears to only be growing. With Novo Nordisk and Eli Lilly dominating the obesity field, Amgen's CEO Robert Bradway knows a new offering will have to offer a unique benefit.

article thumbnail

Patented AI Platform Identifies Promising Early-Stage BioPharma Assets and Companies

Fierce Pharma

Authors: | Gain the competitive edge with accurate probability of success assessments to uncover undervalued companies and early-stage assets for acquisitions.

Biopharma 177
article thumbnail

The New Radiopharma Competition Requires Unprecedented Medical Logistics

MedCity News

As the innovative, multi-billion dollar industry expands rapidly, pharma companies must consider how to deliver and differentiate. The post The New Radiopharma Competition Requires Unprecedented Medical Logistics appeared first on MedCity News.

article thumbnail

FTC Sees Red Over Alleged Misuse of FDA Orange Book, Puts 10 Pharmas on Notice

MedCity News

The Federal Trade Commission says more than 100 patents from 10 biopharma companies are improperly listed in the FDA’s official publication of approved products. Such listings delay generic competition, which reduces consumer choice and keeps prices high, the regulator said.

Biopharma 135